As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
The rapid study startup process can ensure studies are finely tuned for scientific validity.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
The rapid study startup process can ensure studies are finely tuned for scientific validity.
